|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
00512 GRAND PHARMA
Nominal 
8.130 -0.120 (-1.455%) | 2025/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2024/12 HKD(K$) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | |
| Turnover | 6,107,323 | 0.994% | 11,644,892 | 10,529,590 | 9,562,285 | 8,597,975 |
| Cost of Sales | (2,507,159) | 2.086% | (4,906,576) | (4,005,524) | (3,610,806) | (3,350,737) |
| Gross Profit | 3,600,164 | 0.247% | 6,738,316 | 6,524,066 | 5,951,479 | 5,247,238 |
| 2025/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2024/12 HKD(K$) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 174,593 | -60.655% | 599,472 | 18,763 | (91,345) | (8,350) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | (73,378) | (58,664) | 23,017 | 484,495 | |
| Share of Results of Asso. & JCEs | 57,944 | 207.951% | 148,720 | (25,008) | (43,786) | 113,862 | |
| Profit / (Loss) before Taxation | 1,347,893 | -26.420% | 2,852,363 | 2,344,197 | 2,516,893 | 2,785,832 | |
| Taxation | (174,023) | -28.730% | (386,304) | (448,755) | (418,642) | (380,800) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (4,851) | -83.701% | 2,316 | (15,444) | (18,832) | (2,469) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 1,169,019 | -24.964% | 2,468,375 | 1,879,998 | 2,079,419 | 2,402,563 | |
| 2025/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2024/12 HKD(K$) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | |
| Net Finance Costs / (Income) | 80,350 | -6.701% | 173,932 | 197,400 | 117,687 | 18,011 |
| Depreciation & Amortisation | 285,424 | 14.555% | 503,748 | 392,210 | 394,912 | 339,519 |
| Directors' Emoluments | -- | -- | 5,900 | 8,988 | 6,357 | 4,554 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 33.380 | -24.837% | 70.490 | 53.600 | 58.700 | 67.720 |
| DPS (cts) | 0.000 | -- | 26.000 | 26.000 | 14.000 | 11.000 |
| Dividend Payout Ratio (%) | -- | -- | 36.885% | 48.507% | 23.850% | 16.243% |
| Cash flow per share ($) | -- | -- | 0.542 | 0.691 | 0.520 | 0.565 |
| NBV per share ($) | 4.833 | -- | 4.641 | 4.270 | 3.984 | 3.773 |
| Remarks: | Real time quote last updated: 28/10/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K$) | HKD 1,169,019 |
| %Change | -24.964% |
| EPS / (LPS) | HKD 0.334 |
| NBV Per Share ($) | HKD 4.833 |